Target Information
General Information of This Target (ID: PATR0RIOXT)
| Target Name | Human deoxyribonucleic acid (hDNA) |
|||||
|---|---|---|---|---|---|---|
| Function |
Deoxyribonucleic acid (DNA) is a polymer composed of two polynucleotide chains that coil around each other to form a double helix. The polymer carries genetic instructions for the development, functioning, growth and reproduction of all known organisms and many viruses. DNA and ribonucleic acid (RNA) are nucleic acids.
Click to Show/Hide
|
|||||
Full List of The ADC Related to This Target
Approved in 2017
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Inotuzumab ozogamicin
[1]
|
Inotuzumab |
B-cell receptor CD22 (CD22) |
N-acetyl-gamma-calicheamicin |
AcButDMH |
|
|
Gemtuzumab ozogamicin
[2]
|
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
N-acetyl-gamma-calicheamicin |
AcButDMH |
|
|
Loncastuximab tesirine
|
Loncastuximab |
B-lymphocyte antigen CD19 (CD19) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
New Drug Application (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Trastuzumab duocarmazine
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
Phase 3 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Rovalpituzumab tesirine
|
Rovalpituzumab |
Delta-like protein 3 (DLL3) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
Vadastuximab talirine
|
Vadastuximab |
Myeloid cell surface antigen CD33 (CD33) |
SGD-1882 |
Mc-Val-Ala |
Phase 2 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Camidanlumab tesirine
|
Camidanlumab |
Interleukin-2 receptor subunit alpha (IL2RA) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
Vobramitamab duocarmazine
|
Vobramitamab |
CD276 antigen (CD276) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
Phase 2 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
CMB-401
|
HCTM01 |
Mucin-1 (MUC1) |
N-acetyl-gamma-calicheamicin |
Amide-based linker |
Apprpved in 2026
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Pivekimab sunirine
|
Pivekimab |
Interleukin-3 receptor subunit alpha (IL3RA) |
DGN549 |
Mal-adipamide-Ala-Ala |
|
|
Epratuzumab-cys-tesirine
|
Epratuzumab |
B-cell receptor CD22 (CD22) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
Phase 1 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Mipasetamab uzoptirine
|
Mipasetamab |
Tyrosine-protein kinase receptor UFO (AXL) |
SG3199 (SC-DR002) |
BCN-HydraSpace-Val-Ala-PABC |
|
|
BYON3521
|
SYD2884 |
Hepatocyte growth factor receptor (MET) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
DS-9606a
|
Anti-CLDN6 antibody |
Claudin-6 (CLDN6) |
PBD dimer |
A cleavable linker |
|
|
LCB73
|
Anti-CD19 antibody |
B-lymphocyte antigen CD19 (CD19) |
PBD dimer |
β-glucuronide trigger linker |
|
|
ABL202
|
Anti-ROR1 IgG1 mAb |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
PBD dimer |
β-glucuronide trigger linker |
|
|
MT-8633
|
HD12 |
Hepatocyte growth factor receptor (MET) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
BYON-4413
|
Anti-CD123 IgG1 mAb |
Interleukin-3 receptor subunit alpha (IL3RA) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
ADCT-701
|
HuBa-1-3D |
Protein delta homolog 1 (DLK1) |
SG3199 (SC-DR002) |
BCN-HydraSpace-Val-Ala-PABC |
|
|
Olintatug tesirine
|
Olintatug |
Kidney-associated antigen 1 (KAAG1) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
Phase 1 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
MEDI2228
|
BCMA-Ab1 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
MEDI3726
|
J591 |
Glutamate carboxypeptidase 2 (FOLH1) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
Rolinsatamab talirine
|
Rolinsatamab |
Prolactin receptor (PRLR) |
SGD-1882 |
Mc-Val-Ala |
|
|
SC-002
|
Rovalpituzumab |
Delta-like protein 3 (DLL3) |
SG3199 (SC-DR002) |
Val-Ala dipeptide linker |
|
|
SC-006
|
Anti-RNF43 antibody |
E3 ubiquitin-protein ligase RNF43 (RNF43) |
SG3312 (SC-DR003) |
Mc-Val-Ala |
|
|
ABBV-011
|
SC17 |
Seizure protein 6 homolog (SEZ6) |
N-acetyl-gamma-calicheamicin |
Mc-PEG8-acid-labile linker |
|
|
Serclutamab talirine
|
Serclutamab |
Epidermal growth factor receptor (EGFR) |
SGD-1882 |
Mc-Val-Ala |
|
|
SYD1875
|
SYD1594 |
Trophoblast glycoprotein (TPBG) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
TAK-164
|
5F9 |
GC-C |
DGN549 |
Mal-adipamide-Ala-Ala |
|
|
Tamrintamab pamozirine
|
Tamrintamab |
Dipeptidase 3 (DPEP3) |
SG3199 (SC-DR002) |
Mc-Val-Ala-PABC |
|
|
ADCT-502
|
Trastuzumab variant |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
CMD-193
|
G193 |
Lewis Y |
N-acetyl-gamma-calicheamicin |
AcButDMH |
|
|
PF-06647263
|
HuE22 |
Ephrin-A4 (EFNA4) |
N-acetyl-gamma-calicheamicin |
AcButDMH |
|
|
RG6148
|
MHES0488A |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
A cleavable disulfide linker |
|
|
SC-007
|
Undisclosed |
Undisclosed |
PBD dimer |
Undisclosed |
|
|
SGN-CD123A
|
h7G3EC |
Interleukin-3 receptor subunit alpha (IL3RA) |
SGD-1882 |
Mc-Val-Ala |
|
|
SGN-CD19B
|
HBU12ec |
B-lymphocyte antigen CD19 (CD19) |
SGD-1882 |
Mc-Val-Ala |
|
|
SGN-CD352A
|
H20F3ec |
SLAM family member 6 (SLAMF6) |
PBD dimer |
Val-Ala dipeptide linker |
|
|
SGN-CD70A
|
H1F6ec |
CD70 antigen (CD70) |
PBD dimer |
dipeptide linker |
|
|
SC-004
|
An antibody targeting CLDN6/9 |
Claudin-6 (CLDN6); Claudin-9 (CLDN9) |
SGD-1882 |
Val-Cit linker |
|
|
BMS-936561
|
MDX-1115 |
CD70 antigen (CD70) |
seco-MED-A |
Mal-Val-Cit |
|
|
IMGN779
|
Z4681A |
Myeloid cell surface antigen CD33 (CD33) |
DGN462 |
Sulfo-SPDB |
|
|
RG6109
|
MCLL0517A |
CLL-1 |
PBD dimer |
A cleavable disulfide linker |
|
|
SC-005
[3]
|
Undisclosed |
Undisclosed |
PBD dimer |
Undisclosed |
|
|
MEDI7247
|
Idactamab |
Amino acid transporter (ASCT2) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
Investigative
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Trastuzumab-Flexmab-SG3710
[4]
|
Trastuzumab-Flexmab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
Trastuzumab-C239I-SG3249
[4]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
Trastuzumab-C239I-SG3600
[5]
|
Engineered trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
N10-beta-glucuronide SG3200 |
Mal-PEG8-Val-Ala-PABC |
|
|
Trastuzumab-C239I-SG3400
[5]
|
Engineered trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3200 |
Mal-PEG8-Val-Ala-PABC |
|
|
Fv-LDP-D3-AE
[6]
|
Fv-LDP-D3 |
Epidermal growth factor receptor (EGFR) |
Lidamycin |
Undisclosed |
|
|
Cetuximab- (FGX16-11)
[7]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
FGX8-46 |
Mc-Val-Ala-PABC |
|
|
D3-GPC2-PBD
[8]
|
Fully human D3-GPC2-IgG1 |
Glypican-2 (GPC2) |
PBD dimer |
Undisclosed |
|
|
Trastuzumab-SG3227
[9]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2219 |
Acetamide-PEG4-Val-Ala-PABA |
|
|
Engineered HER-SG3227
[9]
|
Engineered trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2219 |
Acetamide-PEG4-Val-Ala-PABA |
|
|
HER-SG3249
[10]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
Site-specific HER-SG3249
[10]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
Trastuzumab-SG3600 high DAR
[5]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
N10-beta-glucuronide SG3200 |
Mal-PEG8-Val-Ala-PABC |
|
|
40H3-Tesirine
[11]
|
Anti-EGFR mAb 40H3 |
Epidermal growth factor receptor (EGFR) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
Anti-CD22- (LC:K149C)-SN36248
[12]
|
Pinatuzumab |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mal-PEG2 |
|
|
AT-03
[13]
|
Anti-CLDN6 antibody |
Claudin-6 (CLDN6) |
TCS132 (AxcynDOT) |
A cleavable linker |
|
|
M276-SL-PBD
[14]
|
Anti-CD276 mAb m276-SL |
CD276 antigen (CD276) |
PBD dimer |
Mc-Val-Ala |
|
|
KTN0182A
[15]
|
Undisclosed |
Mast/stem cell growth factor receptor Kit (KIT) |
PBD dimer |
Undisclosed |
|
|
EV20/NMS-P945
[16]
|
EV20 |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
NMS-P528 |
Cathepsin-cleavable peptidic linker with self-immolating spacer |
|
|
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Gly-Calicheamicin
[17]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Gly-calicheamicin |
BCN-HydraSpace-Val-Cit-PABC |
|
|
Trastuzumab SG-3259
[18]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3312 |
Mc-Val-Ala |
|
|
Trastuzumab-SG3400 high DAR
[5]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG3200 |
Mal-PEG8-Val-Ala-PABC |
|
|
Promiximab-DUBA
[19]
|
Promiximab |
Neural cell adhesion molecule 1 (NCAM1) |
Seco-DUBA |
Mal-Val-Cit-PABA-Cyclization spacer |
|
|
MUC16-Mc-Val-Cit-PABC-CBI dimer
[20]
|
Thio hu Anti-MUC16 |
Mucin-16 (MUC16) |
seco-CBI-dimer |
Mc-Val-Cit-PABC |
|
|
Anti-CD22-SN36248
[12]
|
Anti-CD22 10F4 Thiomab (LC:K149C) |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mal-PEG2 |
|
|
T1LD7
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-acetyl-gamma-calicheamicin |
Mal-Val-Cit-PABC-EDA |
|
|
Recombinant humanized anti-EGFR mAb-DUO-5 conjugate
[22]
|
Undisclosed |
Epidermal growth factor receptor (EGFR) |
Duostatin 5 |
Undisclosed |
|
|
HuB4-DGN462
[23]
|
Undisclosed |
B-lymphocyte antigen CD19 (CD19) |
DGN462 |
Sulfo-SPDB |
|
|
B4-SPP-DC44
[24]
|
Anti-CD19 mAb B4 |
B-lymphocyte antigen CD19 (CD19) |
DC44 |
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP) |
|
|
HuC242-SPP-DC4
[24]
|
Cantuzumab |
Syndecan-1 (SDC1) |
Phosphate prodrugs 40 (DC4) |
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP) |
|
|
HuC242-SPDB-DC4
[24]
|
Cantuzumab |
Syndecan-1 (SDC1) |
Phosphate prodrugs 40 (DC4) |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB) |
|
|
HuC242-SMCC-DC4
[24]
|
Cantuzumab |
Syndecan-1 (SDC1) |
Phosphate prodrugs 40 (DC4) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
|
|
B4-SMCC-DC4
[24]
|
Anti-CD19 mAb B4 |
B-lymphocyte antigen CD19 (CD19) |
Phosphate prodrugs 40 (DC4) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
|
|
B4-SPP-DC4
[24]
|
Anti-CD19 mAb B4 |
B-lymphocyte antigen CD19 (CD19) |
Phosphate prodrugs 40 (DC4) |
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP) |
|
|
B4-SPP-DC1
[24]
|
Anti-CD19 mAb B4 |
B-lymphocyte antigen CD19 (CD19) |
DC1 |
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP) |
|
|
Anti-B4 monoclonal antibody-DC1 conjugate
[25]
|
Undisclosed |
B-lymphocyte antigen CD19 (CD19) |
DC1 |
Undisclosed |
|
|
REGN-3124-PBD
[26]
|
REGN3124 |
Epidermal growth factor receptor variant III (EGFRvIII) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
CD25-ADC
[27]
|
Anti-CD25 mAb PC61 |
Interferon-stimulated gene 20 kDa protein (ISG20) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
HLL2-PBD
[28]
|
Epratuzumab |
B-cell receptor CD22 (CD22) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
GFRA1 targeted antibody-drug conjugate
[29]
|
Anti-GFRA1 mAb |
GDNF family receptor alpha-1 (GFRA1) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
MEDI-0641
[30]
|
5T4_0108 |
Trophoblast glycoprotein (TPBG) |
5T4-PBD |
Mal-PEG8-Val-Ala-PABC |
|
|
Anti-CD30-LDM
[31]
|
Recombinant human CD30Fc fusion protein |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Lidamycin |
Uncleavable linker |
|
|
NV105
[32]
|
Undisclosed |
CD276 antigen (CD276) |
Temozolomide |
Undisclosed |
|
|
CD33-CPI dimer ADC
[33]
|
Anti-CD33 Anti-ody 11A1 |
Myeloid cell surface antigen CD33 (CD33) |
Bicyclopentyl-seco-CBI-dimer |
AcLys-Val-Cit-PABC-DMAE |
|
|
HuN901-CC-1065
[34]
|
Lorvotuzumab |
Neural cell adhesion molecule 1 (NCAM1) |
Rachelmycin |
Cleavable disulfide |
|
|
Monoclonal antibody A5B7-cisplatin conjugate
[35]
|
Anti-CEACAM5 mAb A5B7 |
Pregnancy-specific beta-1-glycoprotein 2 (PSG2) |
Cisplatin |
Undisclosed |
|
|
PYX-203
[36]
|
Undisclosed |
Interleukin-3 receptor subunit alpha (IL3RA) |
Cyclopropylpyrroloindole (CPI) DNA-damaging payload |
Lysosomal cleavable linker |
|
|
CD123-CPI ADC (Pfizer)
[37]
|
Undisclosed |
Interleukin-3 receptor subunit alpha (IL3RA) |
Cyclopropylpyrroloindoline (CPI) payload |
Undisclosed |
|
|
CLL1-ADC
[38]
|
Fully humanized Anti-CLL1 mAb |
C-type lectin domain family 12 member A (CLEC12A) |
D211 |
Mal-PEG8-Val-Cit-PABC |
|
|
CyEt-Pan-Duo
[39]
|
Panitumumab |
Epidermal growth factor receptor (EGFR) |
DEAEA duocarmycin |
Mal-PEG4-Triazol-Cyanine cage |
|
|
Anti-PDGFRB cotinine scFv-C-scFv-duocarmycin
[40]
|
Bispecific Anti-PDGFRB + cotinine scFv-C-scFv fusion protein |
Platelet-derived growth factor receptor beta (PDGFRB) |
DEAEA duocarmycin |
PEG3-Val-Cit-PABC |
|
|
RC58-ADC-1
[41]
|
RC58 |
B-lymphocyte antigen CD19 (CD19) |
Dumycin-7 |
Bis-bromine linker-PEG4-Asn-Ala-ethylenediamine |
|
|
D2B-DCM
[42]
|
Anti-PSMA mAb D2B |
Glutamate carboxypeptidase 2 (FOLH1) |
Duocarmycin A |
Mc-Val-Cit-PABC |
|
|
B2M-duocarmycin ADC
[43]
|
LS-B2200 |
Beta-2-microglobulin (B2M) |
Duocarmycin A |
Bis-Tolylsulfonyl-Propanoyl-Benzamide-Glu-NH-PEG(24u)-OMe-Val-Cit-PAB |
|
|
Anti-PDGFRB C-scFv Duocarmycin
[40]
|
Anti-mouse PDGFRB Anti-ody |
Platelet-derived growth factor receptor beta (PDGFRB) |
Duocarmycin A |
Undisclosed |
|
|
ENDOS/ADC
[44]
|
Anti-CD248 mAb hMP-E-8.3 |
Endosialin (CD248) |
Duocarmycin derivative |
Val-Cit |
|
|
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Duocarmycin
[17]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Duocarmycin Sa |
BCN-HydraSpace-Val-Cit-PABC |
|
|
HYP7-DC
[45]
|
Humanized GPC3-specific Anti-ody YP7 |
Glypican-3 (GPC3) |
Duocarmycin Sa |
Mal-PEG4-Val-Cit-PABC-DMAE |
|
|
PCM5B14-DCM
[46]
|
H5B14 |
Macrophage-stimulating protein receptor (MST1R) |
Duocarmycin Sa |
Mc-PEG4-Val-Cit-PABC-DMAE |
|
|
Cotinine-duocarmycin
[40]
|
ERC6 bispecific Anti-ody (fuse Anti-cotinine scFv to cetuximab CH3 domain) |
Epidermal growth factor receptor (EGFR) |
Duocarmycin Sa |
Mc-Val-Cit-PABC-DMAE |
|
|
GPR56-ADC
[47]
|
Anti-GPR56 Anti-ody 10C7 |
Adhesion G-protein coupled receptor G1 (ADGRG1) |
Duocarmycin Sa |
Mal-Val-Cit-PABC-DMEA-PEG2 |
|
|
ZV-0508
[48]
|
ZV05 |
Trophoblast glycoprotein (TPBG) |
Duostatin 5 |
C-Lock-ANN tri-peptide |
|
|
Adalimumab fosimdesonide
[49]
|
Adalimumab |
Tumor necrosis factor (TNF) |
SGD-1882 |
Undisclosed |
|
|
CIRCR201-dPBD
[50]
|
Anti-MET mAb cIRCR201 |
Hepatocyte growth factor receptor (MET) |
Glucuronide-dPBD |
Iso-PEG5-beta-glucuronide |
|
|
LA22-MMC
[51]
|
Anti-EGFR mAb LA22 |
Epidermal growth factor receptor (EGFR) |
Mitomycin C |
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) |
|
|
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Calicheamicin
[17]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
N-acetyl-gamma-calicheamicin |
BCN-HydraSpace-Val-Cit-PABC |
|
|
T1LD6
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-methyl-uncialamycin |
Mal-Val-Cit-gucuronide-PEG8-PABC |
|
|
T1LD5
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-methyl-uncialamycin |
Mal-Val-Cit-glucuronide-PABC |
|
|
T1LD4
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-methyl-uncialamycin |
Mal-glucuronidase cleavable linker |
|
|
T1LD3
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-methyl-uncialamycin |
Mal-PEG8 |
|
|
T1LD2
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-methyl-uncialamycin |
Mal-acetic acid |
|
|
T1LD1
[21]
|
Anti-IL1RL1 mAb |
Interleukin-1 receptor-like 1 (IL1RL1) |
N-methyl-uncialamycin |
Mal-Val-Cit-PABC |
|
|
T2LD6
[21]
|
Anti-CD46 mAb |
Membrane cofactor protein (CD46) |
N-methyl-uncialamycin |
Mal-Val-Cit-gucuronide-PEG8-PABC |
|
|
T2LD5
[21]
|
Anti-CD46 mAb |
Membrane cofactor protein (CD46) |
N-methyl-uncialamycin |
Mal-Val-Cit-glucuronide-PABC |
|
|
T2LD4
[21]
|
Anti-CD46 mAb |
Membrane cofactor protein (CD46) |
N-methyl-uncialamycin |
Mal-glucuronidase cleavable linker |
|
|
T2LD3
[21]
|
Anti-CD46 mAb |
Membrane cofactor protein (CD46) |
N-methyl-uncialamycin |
Mal-PEG8 |
|
|
T2LD2
[21]
|
Anti-CD46 mAb |
Membrane cofactor protein (CD46) |
N-methyl-uncialamycin |
Mal-acetic acid |
|
|
T2LD1
[21]
|
Anti-CD46 mAb |
Membrane cofactor protein (CD46) |
N-methyl-uncialamycin |
Mal-Val-Cit-PABC |
|
|
ACD22-LC-K149C-10
[52]
|
Anti-CD22-LC-K149C |
B-cell receptor CD22 (CD22) |
PA-seco-CBI-dimer |
Mc-cBu-Cit |
|
|
Anti-ICOS-PBD
[53]
|
Murine Anti-ICOS Anti-ody |
Inducible T-cell costimulator (ICOS) |
PBD dimer |
Undisclosed |
|
|
Masked ADC (Adagene/ADC Therapeutics)
[54]
|
Undisclosed |
Undisclosed |
PBD dimer |
Undisclosed |
|
|
Trastuzumab-BCN-HydraSpace-Val-Ala-PABC-PBD dimer
[17]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer 2 |
BCN-HydraSpace-Val-Ala-PABC |
|
|
Trastuzumab-DNA mimic 4
[55]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Q Pho-DNA mimics |
Diphenyltio-Mal-Cap |
|
|
ADCT-211
[56]
|
Anti-IL13RA2 mAb huCl47 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
SG2000 |
Vali-Ala cleavable linker |
|
|
ADCT-212
[57]
|
Undisclosed |
Prostate-specific antigen (KLK3) |
SG2000 |
Vali-Ala cleavable linker |
|
|
Anti-IL13RA2 PBD ADC
[58]
|
Anti-IL13RA2 mAb 2E10 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
SGD-1882 |
Mc-Val-Ala |
|
|
111In-DOTA-5D3
[59]
|
Anti-PSMA mAb 5D3 |
Glutamate carboxypeptidase 2 (FOLH1) |
Indium-111 |
Tetraxetan |
|
|
Anti-FucGM1-45 ADC
[60]
|
Anti-FucGM1 mAb |
Fucosylated monosialotetrahexosylganglioside (FucGM1) |
Tetrahydroisoquinoline-based PBD dimer 17 |
Mc-Val-Cit-PABC |
|
|
Anti-FucGM1-46 ADC
[60]
|
Anti-FucGM1 mAb |
Fucosylated monosialotetrahexosylganglioside (FucGM1) |
Tetrahydroisoquinoline-based PBD dimer 17 |
PEG2-Val-Cit-PABC |
|
|
Anti-FucGM1-47 ADC
[60]
|
Anti-FucGM1 mAb |
Fucosylated monosialotetrahexosylganglioside (FucGM1) |
Tetrahydroisoquinoline-based PBD dimer 17 |
PEG4-Val-Cit-PABC |
|
|
Anti-FucGM1-48 ADC
[60]
|
Anti-FucGM1 mAb |
Fucosylated monosialotetrahexosylganglioside (FucGM1) |
Tetrahydroisoquinoline-based PBD dimer 17 |
PEG8-Val-Cit-PABC |
|
|
Anti-CD70-45 ADC
[60]
|
Anti-CD70 mAb |
CD70 antigen (CD70) |
Tetrahydroisoquinoline-based PBD dimer 17 |
Mc-Val-Cit-PABC |
|
|
Anti-MSLN-45 ADC
[60]
|
Anti-MSLN mAb |
Mesothelin (MSLN) |
Tetrahydroisoquinoline-based PBD dimer 17 |
Mc-Val-Cit-PABC |
|
|
Anti-MSLN-46 ADC
[60]
|
Anti-MSLN mAb |
Mesothelin (MSLN) |
Tetrahydroisoquinoline-based PBD dimer 17 |
PEG2-Val-Cit-PABC |
|
|
Anti-MSLN-47 ADC
[60]
|
Anti-MSLN mAb |
Mesothelin (MSLN) |
Tetrahydroisoquinoline-based PBD dimer 17 |
PEG4-Val-Cit-PABC |
|
|
Anti-MSLN-48 ADC
[60]
|
Anti-MSLN mAb |
Mesothelin (MSLN) |
Tetrahydroisoquinoline-based PBD dimer 17 |
PEG8-Val-Cit-PABC |
|
|
Anti-MSLN-44 ADC
[60]
|
Anti-MSLN mAb |
Mesothelin (MSLN) |
Tetrahydroisoquinoline-based PBD dimer 14 |
Mal-PEG8-Val-Cit-PABC |
|
|
IKS-01
[61]
|
Isumab01 |
Folate receptor alpha (FOLR1) |
FGX2-62 |
Undisclosed |
|
|
IPH43
[62]
|
Glycosylated Anti-MICA Anti-ody |
MHC class I polypeptide-related sequence A (MICA) |
PBD dimer |
Undisclosed |
|
|
SC16.3-DL2
[63]
|
SC16.3 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.4-DL2
[63]
|
SC16.4 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.5-DL2
[63]
|
SC16.5 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.7-DL2
[63]
|
SC16.7 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.8-DL2
[63]
|
SC16.8 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.10-DL2
[63]
|
SC16.10 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.11-DL2
[63]
|
SC16.11 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.13-DL2
[63]
|
SC16.13 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.15-DL2
[63]
|
SC16.15 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.18-DL2
[63]
|
SC16.18 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.19-DL2
[63]
|
SC16.19 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.20-DL2
[63]
|
SC16.20 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.21-DL2
[63]
|
SC16.21 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.22-DL2
[63]
|
SC16.22 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.23-DL2
[63]
|
SC16.23 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.25-DL2
[63]
|
SC16.25 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.26-DL2
[63]
|
SC16.26 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.29-DL2
[63]
|
SC16.29 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.30-DL2
[63]
|
SC16.30 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.31-DL2
[63]
|
SC16.31 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.34-DL2
[63]
|
SC16.34 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.35-DL2
[63]
|
SC16.35 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.36-DL2
[63]
|
SC16.36 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.38-DL2
[63]
|
SC16.38 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.41-DL2
[63]
|
SC16.41 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.42-DL2
[63]
|
SC16.42 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.45-DL2
[63]
|
SC16.45 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.47-DL2
[63]
|
SC16.47 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.49-DL2
[63]
|
SC16.49 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.50-DL2
[63]
|
SC16.50 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.52-DL2
[63]
|
SC16.52 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.55-DL2
[63]
|
SC16.55 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.56-DL2
[63]
|
SC16.56 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.57-DL2
[63]
|
SC16.57 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.58-DL2
[63]
|
SC16.58 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.61-DL2
[63]
|
SC16.61 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.62-DL2
[63]
|
SC16.62 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.63-DL2
[63]
|
SC16.63 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.65-DL2
[63]
|
SC16.65 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.67-DL2
[63]
|
SC16.67 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.68-DL2
[63]
|
SC16.68 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.72-DL2
[63]
|
SC16.72 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.73-DL2
[63]
|
SC16.73 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.78-DL2
[63]
|
SC16.78 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.79-DL2
[63]
|
SC16.79 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.80-DL2
[63]
|
SC16.80 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.81-DL2
[63]
|
SC16.81 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.84-DL2
[63]
|
SC16.84 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.88-DL2
[63]
|
SC16.88 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.101-DL2
[63]
|
SC16.101 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.103-DL2
[63]
|
SC16.103 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.104-DL2
[63]
|
SC16.104 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.105-DL2
[63]
|
SC16.105 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.106-DL2
[63]
|
SC16.106 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.107-DL2
[63]
|
SC16.107 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.108-DL2
[63]
|
SC16.108 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.109-DL2
[63]
|
SC16.109 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.110-DL2
[63]
|
SC16.110 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.111-DL2
[63]
|
SC16.111 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.113-DL2
[63]
|
SC16.113 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.114-DL2
[63]
|
SC16.114 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.115-DL2
[63]
|
SC16.115 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.116-DL2
[63]
|
SC16.116 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.117-DL2
[63]
|
SC16.117 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.118-DL2
[63]
|
SC16.118 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.120-DL2
[63]
|
SC16.120 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.121-DL2
[63]
|
SC16.121 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.122-DL2
[63]
|
SC16.122 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.123-DL2
[63]
|
SC16.123 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.124-DL2
[63]
|
SC16.124 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.125-DL2
[63]
|
SC16.125 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.126-DL2
[63]
|
SC16.126 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.129-DL2
[63]
|
SC16.129 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.130-DL2
[63]
|
SC16.130 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.131-DL2
[63]
|
SC16.131 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.132-DL2
[63]
|
SC16.132 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.133-DL2
[63]
|
SC16.133 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.134-DL2
[63]
|
SC16.134 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.135-DL2
[63]
|
SC16.135 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.136-DL2
[63]
|
SC16.136 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.137-DL2
[63]
|
SC16.137 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.138-DL2
[63]
|
SC16.138 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.139-DL2
[63]
|
SC16.139 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.140-DL2
[63]
|
SC16.140 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.141-DL2
[63]
|
SC16.141 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.142-DL2
[63]
|
SC16.142 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.143-DL2
[63]
|
SC16.143 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.144-DL2
[63]
|
SC16.144 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.147-DL2
[63]
|
SC16.147 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.148-DL2
[63]
|
SC16.148 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.149-DL2
[63]
|
SC16.149 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.150-DL2
[63]
|
SC16.150 |
Delta-like protein 3 (DLL3) |
SG3312 |
Mc-Val-Ala |
|
|
SC16.3-DL3
[63]
|
SC16.3 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.4-DL3
[63]
|
SC16.4 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.5-DL3
[63]
|
SC16.5 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.7-DL3
[63]
|
SC16.7 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.8-DL3
[63]
|
SC16.8 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.10-DL3
[63]
|
SC16.10 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.11-DL3
[63]
|
SC16.11 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.13-DL3
[63]
|
SC16.13 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.15-DL3
[63]
|
SC16.15 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.18-DL3
[63]
|
SC16.18 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.19-DL3
[63]
|
SC16.19 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.20-DL3
[63]
|
SC16.20 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.21-DL3
[63]
|
SC16.21 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.22-DL3
[63]
|
SC16.22 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.23-DL3
[63]
|
SC16.23 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.25-DL3
[63]
|
SC16.25 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.26-DL3
[63]
|
SC16.26 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.29-DL3
[63]
|
SC16.29 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.30-DL3
[63]
|
SC16.30 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.31-DL3
[63]
|
SC16.31 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.34-DL3
[63]
|
SC16.34 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.35-DL3
[63]
|
SC16.35 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.36-DL3
[63]
|
SC16.36 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.38-DL3
[63]
|
SC16.38 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.41-DL3
[63]
|
SC16.41 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.42-DL3
[63]
|
SC16.42 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.45-DL3
[63]
|
SC16.45 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.47-DL3
[63]
|
SC16.47 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.49-DL3
[63]
|
SC16.49 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.50-DL3
[63]
|
SC16.50 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.52-DL3
[63]
|
SC16.52 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.55-DL3
[63]
|
SC16.55 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.56-DL3
[63]
|
SC16.56 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.57-DL3
[63]
|
SC16.57 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.58-DL3
[63]
|
SC16.58 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.61-DL3
[63]
|
SC16.61 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.62-DL3
[63]
|
SC16.62 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.63-DL3
[63]
|
SC16.63 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.65-DL3
[63]
|
SC16.65 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.67-DL3
[63]
|
SC16.67 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.68-DL3
[63]
|
SC16.68 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.72-DL3
[63]
|
SC16.72 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.73-DL3
[63]
|
SC16.73 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.78-DL3
[63]
|
SC16.78 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.79-DL3
[63]
|
SC16.79 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.80-DL3
[63]
|
SC16.80 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.81-DL3
[63]
|
SC16.81 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.84-DL3
[63]
|
SC16.84 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.88-DL3
[63]
|
SC16.88 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.101-DL3
[63]
|
SC16.101 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.103-DL3
[63]
|
SC16.103 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.104-DL3
[63]
|
SC16.104 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.105-DL3
[63]
|
SC16.105 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.106-DL3
[63]
|
SC16.106 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.107-DL3
[63]
|
SC16.107 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.108-DL3
[63]
|
SC16.108 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.109-DL3
[63]
|
SC16.109 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.110-DL3
[63]
|
SC16.110 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.111-DL3
[63]
|
SC16.111 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.113-DL3
[63]
|
SC16.113 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.114-DL3
[63]
|
SC16.114 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.115-DL3
[63]
|
SC16.115 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.116-DL3
[63]
|
SC16.116 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.117-DL3
[63]
|
SC16.117 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.118-DL3
[63]
|
SC16.118 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.120-DL3
[63]
|
SC16.120 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.121-DL3
[63]
|
SC16.121 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.122-DL3
[63]
|
SC16.122 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.123-DL3
[63]
|
SC16.123 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.124-DL3
[63]
|
SC16.124 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.125-DL3
[63]
|
SC16.125 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.126-DL3
[63]
|
SC16.126 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.129-DL3
[63]
|
SC16.129 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.130-DL3
[63]
|
SC16.130 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.131-DL3
[63]
|
SC16.131 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.132-DL3
[63]
|
SC16.132 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.133-DL3
[63]
|
SC16.133 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.134-DL3
[63]
|
SC16.134 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.135-DL3
[63]
|
SC16.135 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.136-DL3
[63]
|
SC16.136 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.137-DL3
[63]
|
SC16.137 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.138-DL3
[63]
|
SC16.138 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.139-DL3
[63]
|
SC16.139 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.140-DL3
[63]
|
SC16.140 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.141-DL3
[63]
|
SC16.141 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.142-DL3
[63]
|
SC16.142 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.143-DL3
[63]
|
SC16.143 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.144-DL3
[63]
|
SC16.144 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.147-DL3
[63]
|
SC16.147 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.148-DL3
[63]
|
SC16.148 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.149-DL3
[63]
|
SC16.149 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.150-DL3
[63]
|
SC16.150 |
Delta-like protein 3 (DLL3) |
SG2000 derivative PBD 3 |
Mal-PEG8-Val-Ala |
|
|
SC16.3-DL4
[63]
|
SC16.3 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.4-DL4
[63]
|
SC16.4 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.5-DL4
[63]
|
SC16.5 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.7-DL4
[63]
|
SC16.7 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.8-DL4
[63]
|
SC16.8 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.10-DL4
[63]
|
SC16.10 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.11-DL4
[63]
|
SC16.11 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.13-DL4
[63]
|
SC16.13 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.15-DL4
[63]
|
SC16.15 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.18-DL4
[63]
|
SC16.18 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.19-DL4
[63]
|
SC16.19 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.20-DL4
[63]
|
SC16.20 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.21-DL4
[63]
|
SC16.21 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.22-DL4
[63]
|
SC16.22 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.23-DL4
[63]
|
SC16.23 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.25-DL4
[63]
|
SC16.25 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.26-DL4
[63]
|
SC16.26 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.29-DL4
[63]
|
SC16.29 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.30-DL4
[63]
|
SC16.30 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.31-DL4
[63]
|
SC16.31 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.34-DL4
[63]
|
SC16.34 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.35-DL4
[63]
|
SC16.35 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.36-DL4
[63]
|
SC16.36 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.38-DL4
[63]
|
SC16.38 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.41-DL4
[63]
|
SC16.41 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.42-DL4
[63]
|
SC16.42 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.45-DL4
[63]
|
SC16.45 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.47-DL4
[63]
|
SC16.47 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.49-DL4
[63]
|
SC16.49 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.50-DL4
[63]
|
SC16.50 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.52-DL4
[63]
|
SC16.52 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.55-DL4
[63]
|
SC16.55 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.56-DL4
[63]
|
SC16.56 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.57-DL4
[63]
|
SC16.57 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.58-DL4
[63]
|
SC16.58 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.61-DL4
[63]
|
SC16.61 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.62-DL4
[63]
|
SC16.62 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.63-DL4
[63]
|
SC16.63 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.65-DL4
[63]
|
SC16.65 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.67-DL4
[63]
|
SC16.67 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.68-DL4
[63]
|
SC16.68 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.72-DL4
[63]
|
SC16.72 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.73-DL4
[63]
|
SC16.73 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.78-DL4
[63]
|
SC16.78 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.79-DL4
[63]
|
SC16.79 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.80-DL4
[63]
|
SC16.80 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.81-DL4
[63]
|
SC16.81 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.84-DL4
[63]
|
SC16.84 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.88-DL4
[63]
|
SC16.88 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.101-DL4
[63]
|
SC16.101 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.103-DL4
[63]
|
SC16.103 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.104-DL4
[63]
|
SC16.104 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.105-DL4
[63]
|
SC16.105 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.106-DL4
[63]
|
SC16.106 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.107-DL4
[63]
|
SC16.107 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.108-DL4
[63]
|
SC16.108 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.109-DL4
[63]
|
SC16.109 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.110-DL4
[63]
|
SC16.110 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.111-DL4
[63]
|
SC16.111 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.113-DL4
[63]
|
SC16.113 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.114-DL4
[63]
|
SC16.114 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.115-DL4
[63]
|
SC16.115 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.116-DL4
[63]
|
SC16.116 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.117-DL4
[63]
|
SC16.117 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.118-DL4
[63]
|
SC16.118 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.120-DL4
[63]
|
SC16.120 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.121-DL4
[63]
|
SC16.121 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.122-DL4
[63]
|
SC16.122 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.123-DL4
[63]
|
SC16.123 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.124-DL4
[63]
|
SC16.124 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.125-DL4
[63]
|
SC16.125 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.126-DL4
[63]
|
SC16.126 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.129-DL4
[63]
|
SC16.129 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.130-DL4
[63]
|
SC16.130 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.131-DL4
[63]
|
SC16.131 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.132-DL4
[63]
|
SC16.132 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.133-DL4
[63]
|
SC16.133 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.134-DL4
[63]
|
SC16.134 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.135-DL4
[63]
|
SC16.135 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.136-DL4
[63]
|
SC16.136 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.137-DL4
[63]
|
SC16.137 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.138-DL4
[63]
|
SC16.138 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.139-DL4
[63]
|
SC16.139 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.140-DL4
[63]
|
SC16.140 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.141-DL4
[63]
|
SC16.141 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.142-DL4
[63]
|
SC16.142 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.143-DL4
[63]
|
SC16.143 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.144-DL4
[63]
|
SC16.144 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.147-DL4
[63]
|
SC16.147 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.148-DL4
[63]
|
SC16.148 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.149-DL4
[63]
|
SC16.149 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.150-DL4
[63]
|
SC16.150 |
Delta-like protein 3 (DLL3) |
SG2219 |
Iodoacetamide-PEG4-Val-Ala-PABC |
|
|
SC16.3-DL5
[63]
|
SC16.3 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.4-DL5
[63]
|
SC16.4 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.5-DL5
[63]
|
SC16.5 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.7-DL5
[63]
|
SC16.7 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.8-DL5
[63]
|
SC16.8 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.10-DL5
[63]
|
SC16.10 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.11-DL5
[63]
|
SC16.11 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.13-DL5
[63]
|
SC16.13 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.15-DL5
[63]
|
SC16.15 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.18-DL5
[63]
|
SC16.18 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.19-DL5
[63]
|
SC16.19 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.20-DL5
[63]
|
SC16.20 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.21-DL5
[63]
|
SC16.21 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.22-DL5
[63]
|
SC16.22 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.23-DL5
[63]
|
SC16.23 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.25-DL5
[63]
|
SC16.25 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.26-DL5
[63]
|
SC16.26 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.29-DL5
[63]
|
SC16.29 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.30-DL5
[63]
|
SC16.30 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.31-DL5
[63]
|
SC16.31 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.34-DL5
[63]
|
SC16.34 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.35-DL5
[63]
|
SC16.35 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.36-DL5
[63]
|
SC16.36 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.38-DL5
[63]
|
SC16.38 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.41-DL5
[63]
|
SC16.41 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.42-DL5
[63]
|
SC16.42 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.45-DL5
[63]
|
SC16.45 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.47-DL5
[63]
|
SC16.47 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.49-DL5
[63]
|
SC16.49 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.50-DL5
[63]
|
SC16.50 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.52-DL5
[63]
|
SC16.52 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.55-DL5
[63]
|
SC16.55 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.56-DL5
[63]
|
SC16.56 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.57-DL5
[63]
|
SC16.57 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.58-DL5
[63]
|
SC16.58 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.61-DL5
[63]
|
SC16.61 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.62-DL5
[63]
|
SC16.62 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.63-DL5
[63]
|
SC16.63 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.65-DL5
[63]
|
SC16.65 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.67-DL5
[63]
|
SC16.67 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.68-DL5
[63]
|
SC16.68 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.72-DL5
[63]
|
SC16.72 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.73-DL5
[63]
|
SC16.73 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.78-DL5
[63]
|
SC16.78 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.79-DL5
[63]
|
SC16.79 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.80-DL5
[63]
|
SC16.80 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.81-DL5
[63]
|
SC16.81 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.84-DL5
[63]
|
SC16.84 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.88-DL5
[63]
|
SC16.88 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.101-DL5
[63]
|
SC16.101 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.103-DL5
[63]
|
SC16.103 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.104-DL5
[63]
|
SC16.104 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.105-DL5
[63]
|
SC16.105 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.106-DL5
[63]
|
SC16.106 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.107-DL5
[63]
|
SC16.107 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.108-DL5
[63]
|
SC16.108 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.109-DL5
[63]
|
SC16.109 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.110-DL5
[63]
|
SC16.110 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.111-DL5
[63]
|
SC16.111 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.113-DL5
[63]
|
SC16.113 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.114-DL5
[63]
|
SC16.114 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.115-DL5
[63]
|
SC16.115 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.116-DL5
[63]
|
SC16.116 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.117-DL5
[63]
|
SC16.117 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.118-DL5
[63]
|
SC16.118 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.120-DL5
[63]
|
SC16.120 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.121-DL5
[63]
|
SC16.121 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.122-DL5
[63]
|
SC16.122 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.123-DL5
[63]
|
SC16.123 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.124-DL5
[63]
|
SC16.124 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.125-DL5
[63]
|
SC16.125 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.126-DL5
[63]
|
SC16.126 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.129-DL5
[63]
|
SC16.129 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.130-DL5
[63]
|
SC16.130 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.131-DL5
[63]
|
SC16.131 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.132-DL5
[63]
|
SC16.132 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.133-DL5
[63]
|
SC16.133 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.134-DL5
[63]
|
SC16.134 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.135-DL5
[63]
|
SC16.135 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.136-DL5
[63]
|
SC16.136 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.137-DL5
[63]
|
SC16.137 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.138-DL5
[63]
|
SC16.138 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.139-DL5
[63]
|
SC16.139 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.140-DL5
[63]
|
SC16.140 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.141-DL5
[63]
|
SC16.141 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.142-DL5
[63]
|
SC16.142 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.143-DL5
[63]
|
SC16.143 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.144-DL5
[63]
|
SC16.144 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.147-DL5
[63]
|
SC16.147 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.148-DL5
[63]
|
SC16.148 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.149-DL5
[63]
|
SC16.149 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
SC16.150-DL5
[63]
|
SC16.150 |
Delta-like protein 3 (DLL3) |
SG3199 |
Mc-PEG8-Val-Ala-PABC |
|
|
HuM25-S239C-PBD-E2
[64]
|
huM25-S239C |
Leucine-rich repeat-containing protein 15 (LRRC15) |
PBD dimer |
Mc-Val-Ala |
|
|
HuAD208.4.1-PBD-DAR2
[64]
|
huAD208.4.1 |
Leucine-rich repeat-containing protein 15 (LRRC15) |
PBD dimer |
Mc-Val-Ala |
|
|
ABT-700 (S238C)-PBD
[65]
|
Telisotuzumab |
Hepatocyte growth factor receptor (MET) |
PBD dimer |
Mc-Val-Ala |
|
|
ADC Trast-14
[66]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer 3 |
Undisclosed |
|
|
ADC Trast-11
[66]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer 3 |
Bis-BCN-modified Val-Cit-PABC linker 10 |
|
|
Anti-ApoD PBD
[67]
|
Anti-ApoD Anti-ody |
Apolipoprotein D (APOD) |
PBD dimer |
Undisclosed |
|
|
111In-1849
[68]
|
Anti-TF mAb 1849 |
Tissue factor (F3) |
Indium-111 |
Undisclosed |
|
|
SNS-622-DUO
[69]
|
SNS-622 |
Aspartyl/asparaginyl beta-hydroxylase (ASPH) |
Duocarmycin A |
Mc-Val-Cit-PABC |
|
|
DAB4-DuoDM
[70]
|
DAB4 |
Lupus La protein (SSB) |
DEAEA duocarmycin |
Mal-PEG4-Val-Cit-PABC |
|
|
Sal5-DuoDM
[70]
|
Sal5 |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
DEAEA duocarmycin |
Mal-PEG4-Val-Cit-PABC |
|
|
ChDAB4-SG3249
[70]
|
Chimeric DAB4 (chDAB4) |
Lupus La protein (SSB) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
B12-SG3249
[70]
|
B12 |
Envelope glycoprotein gp160 (env) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
Rituximab-DNA conjugate
[71]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DNA mimics |
Undisclosed |
|
|
Cetuximab-DNA conjugate
[71]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
DNA mimics |
Undisclosed |
|
|
Panitumumab-DNA conjugate
[71]
|
Panitumumab |
Epidermal growth factor receptor (EGFR) |
DNA mimics |
Undisclosed |
|
|
Trastuzumab-DNA conjugate
[71]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DNA mimics |
Undisclosed |
|
|
OHPAS ADC-2
[72]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
Ortho-hydroxy-protected aryl sulfate |
|
|
OHPAS ADC-3
[72]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
seco-CBI-indole |
Ortho-hydroxy-protected aryl sulfate |
|
|
OHPAS ADC-4
[72]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
CBI-dimer-beta-Gal |
Ortho-hydroxy-protected aryl sulfate |
|
|
AF-GPL
[73]
|
Anti-ody fragment (AF) |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
Gemcitabine and paclitaxel loaded liposome |
Undisclosed |
|
|
HmAb-C-DUBA
[74]
|
hmAb-C |
CD276 antigen (CD276) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
Alpha-HER2-Duo 405
[75]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Duocarmycin 405 |
Undisclosed |
|
|
WO2021044208A1 ADC6
[76]
|
Anti-ROR1 mAb C2E3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC6 linker |
|
|
WO2021044208A1 ADC7
[76]
|
Anti-ROR1 mAb C2E3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC7 linker |
|
|
WO2021044208A1 ADC8
[76]
|
Anti-ROR1 mAb C2E3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC8 linker |
|
|
WO2021044208A1 ADC 2A2-6
[76]
|
Anti-ROR1 mAb 2A2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC 2A2-6 linker |
|
|
WO2021044208A1 ADC 2A2-7
[76]
|
Anti-ROR1 mAb 2A2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC 2A2-7 linker |
|
|
WO2021044208A1 ADC AB4-1
[76]
|
Anti-ROR1 mAb 2A2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC AB4-1 linker |
|
|
WO2021044208A1 ADC AB4-6
[76]
|
Anti-ROR1 mAb AB4 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC AB4-6 linker |
|
|
WO2021044208A1 ADC AB4-7
[76]
|
Anti-ROR1 mAb AB4 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC AB4-7 linker |
|
|
WO2021044208A1 ADC A2F2-1
[76]
|
Anti-ROR1 mAb AB4 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2-1 linker |
|
|
WO2021044208A1 ADC A2F2-6
[76]
|
Anti-ROR1 mAb A2F2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2-6 linker |
|
|
WO2021044208A1 ADC A2F2-7
[76]
|
Anti-ROR1 mAb A2F2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2-7 linker |
|
|
WO2021044208A1 ADC A2F3-1
[76]
|
Anti-ROR1 mAb A2F2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F3-1 linker |
|
|
WO2021044208A1 ADC A2F3-6
[76]
|
Anti-ROR1 mAb A2F3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F3-6 linker |
|
|
WO2021044208A1 ADC A2F3-7
[76]
|
Anti-ROR1 mAb A2F3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F3-7 linker |
|
|
WO2021044208A1 ADC BA6-1
[76]
|
Anti-ROR1 mAb A2F3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC BA6-1 linker |
|
|
WO2021044208A1 ADC BA6-6
[76]
|
Anti-ROR1 mAb BA6 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC BA6-6 linker |
|
|
WO2021044208A1 ADC BA6-7
[76]
|
Anti-ROR1 mAb BA6 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC BA6-7 linker |
|
|
WO2021044208A1 ADC CC9-1
[76]
|
Anti-ROR1 mAb BA6 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC CC9-1 linker |
|
|
WO2021044208A1 ADC CC9-6
[76]
|
Anti-ROR1 mAb CC9 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC CC9-6 linker |
|
|
WO2021044208A1 ADC CC9-7
[76]
|
Anti-ROR1 mAb CC9 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC CC9-7 linker |
|
|
WO2021044208A1 ADC DG6-1
[76]
|
Anti-ROR1 mAb CC9 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC DG6-1 linker |
|
|
WO2021044208A1 ADC DG6-6
[76]
|
Anti-ROR1 mAb DG6 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC DG6-6 linker |
|
|
WO2021044208A1 ADC DG6-7
[76]
|
Anti-ROR1 mAb DG6 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC DG6-7 linker |
|
|
WO2021044208A1 ADC D2B12-1
[76]
|
Anti-ROR1 mAb DG6 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC D2B12-1 linker |
|
|
WO2021044208A1 ADC D2B12-6
[76]
|
Anti-ROR1 mAb D2B12 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC D2B12-6 linker |
|
|
WO2021044208A1 ADC D2B12-7
[76]
|
Anti-ROR1 mAb D2B12 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC D2B12-7 linker |
|
|
WO2021044208A1 ADC A2F2 M1-1
[76]
|
Anti-ROR1 mAb D2B12 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2 M1-1 linker |
|
|
WO2021044208A1 ADC A2F2 M1-6
[76]
|
Anti-ROR1 mAb A2F2 M1 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2 M1-6 linker |
|
|
WO2021044208A1 ADC A2F2 M1-6
[76]
|
Anti-ROR1 mAb A2F2 M1 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2 M1-7 linker |
|
|
WO2021044208A1 ADC A2F2 M1-7
[76]
|
Anti-ROR1 mAb A2F2 M1 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
SG2000 |
WO2021044208A1_ADC A2F2 M1-7 linker |
|
|
WO2013055987A1 Tmab-101
[77]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
WO2013055987A1_Tmab-101 linker |
|
|
WO2013055987A1 Tmab-102
[77]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
WO2013055987A1_Tmab-102 linker |
|
|
WO2013055987A1 xCD22-103
[77]
|
Anti-CD22 mAb xCD22 |
B-cell receptor CD22 (CD22) |
SG2000 |
WO2013055987A1_xCD22-103 linker |
|
|
WO2013055987A1 Tmab-104
[77]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
WO2013055987A1_Tmab-104 linker |
|
|
WO2013055987A1 Tmab-110
[77]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
WO2013055987A1_Tmab-110 linker |
|
|
Anti-c-Met IgG-OXA
[78]
|
Anti-MET mAb |
Hepatocyte growth factor receptor (MET) |
Oxaliplatin |
Dipeptide-p-amidobenzyl alcohol linker |
|
|
Dualtargeting lidamycin ADC
[79]
|
Undisclosed |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-2 (HER2) |
Lidamycin |
Undisclosed |
|
|
PF-06888667
[80]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SW-163D |
AcLys-Val-Cit-PABC-DMAE |
|
|
Anti-FOLR1-Ala-Ala-IGN
[81]
|
Anti-FOLR1 mAb |
Folate receptor alpha (FOLR1) |
Indolinobenzodiazepine dimer |
Ala-Ala dipeptide |
|
|
Anti-FOLR1-Val-Gln-IGN
[81]
|
Anti-FOLR1 mAb |
Folate receptor alpha (FOLR1) |
Indolinobenzodiazepine dimer |
Val-Gln dipeptide linker |
|
|
Anti-EGFR-Ala-Ala-IGN
[81]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
Indolinobenzodiazepine dimer |
Ala-Ala dipeptide |
|
|
Anti-EGFR-Val-Gln-IGN
[81]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
Indolinobenzodiazepine dimer |
Val-Gln dipeptide linker |
|
|
Tb074-SG3376
[82]
|
Anti-HpHbR mAb Tb074 |
Haptoglobin-hemoglobin receptor (Tb06.28F21.220) |
PBD dimer SG3552 |
Mal-PEG4 |
|
|
Tb085-SG3376
[82]
|
Anti-HpHbR mAb Tb085 |
Haptoglobin-hemoglobin receptor (Tb06.28F21.220) |
PBD dimer SG3552 |
Mal-PEG4 |
|
|
CDX-0125-TEI
[83]
|
Anti-ALK mAb DX-0125 |
ALK tyrosine kinase receptor (ALK) |
NMS-P945 |
Undisclosed |
|
|
Anti-CLL-1-ds-PBD
[84]
|
Anti-CLL-1 THIOMAB Anti-ody |
C-type lectin domain family 12 member A (CLEC12A) |
SG2000 |
Undisclosed |
|
|
HER2-HC-H-SS-PBD
[85]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
H-disulfide linker |
|
|
HER2-LC-H-SS-PBD
[85]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
H-disulfide linker |
|
|
HER2-HC-Me-SS-PBD
[85]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
Me-disulfide linker |
|
|
HER2-LC-Me-SS-PBD
[85]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SG2000 |
Me-disulfide linker |
|
|
Alpha-CD22-LC-K149C-10
[86]
|
Anti-CD22-LC-K149C |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mc-peptidomimetic based linker 10 |
|
|
Alpha-NaPi2b-LC-K149C-10
[86]
|
Anti-NaPi2b-LC-K149C |
Sodium-dependent phosphate transport protein 2B (SLC34A2) |
seco-CBI-dimer |
Mc-peptidomimetic based linker 10 |
|
|
Alpha-Ly6E-LC-K149C-10
[86]
|
Anti-Ly6E-LC-K149C |
Envelope glycoprotein D (Gd) |
seco-CBI-dimer |
Mc-peptidomimetic based linker 10 |
|
|
Alpha-gD-LC-K149C-10
[86]
|
Anti-gD-LC-K149C |
Lymphocyte antigen 6E (LY6E) |
seco-CBI-dimer |
Mc-peptidomimetic based linker 10 |
|
|
Alpha-CD22-LC-K149C-11
[86]
|
Anti-CD22-LC-K149C |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mal-PEG2 |
|
|
Alpha-NaPi2b-LC-K149C-11
[86]
|
Anti-NaPi2b-LC-K149C |
Sodium-dependent phosphate transport protein 2B (SLC34A2) |
seco-CBI-dimer |
Mal-PEG2 |
|
|
Alpha-Ly6E-LC-K149C-11
[86]
|
Anti-Ly6E-LC-K149C |
Lymphocyte antigen 6E (LY6E) |
seco-CBI-dimer |
Mal-PEG2 |
|
|
Alpha-CD22-LC-V205C-10
[86]
|
Anti-CD22-LC-V205C |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mc-peptidomimetic based linker 10 |
|
|
Alpha-CD22-HC-A140C-10
[86]
|
Anti-CD22-HC-A140C |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mc-peptidomimetic based linker 10 |
|
|
Alpha-CD22-HC-A140C-11
[86]
|
Anti-CD22-HC-A140C |
B-cell receptor CD22 (CD22) |
seco-CBI-dimer |
Mc-PEG2 |
|
|
Alpha-CD22-LC-K149C-12
[86]
|
Anti-CD22-LC-K149C |
B-cell receptor CD22 (CD22) |
Seco-CBI-dimer 12 |
Mc-peptidomimetic based linker 12 |
|
|
Alpha-gD-LC-K149C-12
[86]
|
Anti-gD-LC-K149C |
Envelope glycoprotein D (Gd) |
Seco-CBI-dimer 12 |
Mc-peptidomimetic based linker 12 |
|
|
T-PBA
[87]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD-based payload 37b3 |
Mc-Val-Ala |
|
|
HD12-SG3249
[88]
|
Anti-MET mAb hD12 |
Hepatocyte growth factor receptor (MET) |
PBD dimer SG3249 |
Mal-PEG8-Val-Ala-PABC |
|
|
HD12-SG3259
[88]
|
Anti-MET mAb hD12 |
Hepatocyte growth factor receptor (MET) |
PBD dimer SG3259 |
Mal-PEG8-Val-Ala-PABC |
|
|
HD12-SG3315
[88]
|
Anti-MET mAb hD12 |
Hepatocyte growth factor receptor (MET) |
PBD dimer SG3315 |
Mal-PEG8-Val-Ala-PABC |
|
|
HD12-SG3246
[88]
|
Anti-MET mAb hD12 |
Hepatocyte growth factor receptor (MET) |
PBD dimer SG3246 |
Mal-PEG8-Val-Ala-PABC |
|
|
HD12-SG3227
[88]
|
Anti-MET mAb hD12 |
Hepatocyte growth factor receptor (MET) |
PBD dimer SG3227 |
Mal-PEG8-Val-Ala-PABC |
|
|
ABBV-322
[89]
|
Depatuxizumab S238C |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Mc-Val-Ala |
|
|
FOLR1-ADC 13a
[90]
|
Anti-FOLR1 mAb |
Folate receptor alpha (FOLR1) |
PBD dimer 13a |
Adipic acid-Val-Ala-PABC |
|
|
FOLR1-ADC 13b
[90]
|
Anti-FOLR1 mAb |
Folate receptor alpha (FOLR1) |
PBD dimer 13b |
Adipic acid-Val-Ala-PABC |
|
|
FOLR1-ADC 13c
[90]
|
Anti-FOLR1 mAb |
Folate receptor alpha (FOLR1) |
PBD dimer 13c |
Adipic acid-Val-Ala-PABC |
|
|
EGFR-ADC 13a
[90]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
PBD dimer 14a |
Adipic acid-Val-Ala-PABC |
|
|
EGFR-ADC 13b
[90]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
PBD dimer 14b |
Adipic acid-Val-Ala-PABC |
|
|
EGFR-ADC 13c
[90]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
PBD dimer 14c |
Adipic acid-Val-Ala-PABC |
|
|
FOLR1-ADC 15
[90]
|
Anti-FOLR1 mAb |
Folate receptor alpha (FOLR1) |
PBD dimer 13c |
Adipic acid-Val-CIt-PABC |
|
|
Anti-BCMA 15B2GL-SG3249
[91]
|
Anti-BCMA antibody 15B2GL |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA 15B2WT-SG3249
[91]
|
Anti-BCMA antibody 15B2WT |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA I09-SG3249
[91]
|
Anti-BCMA antibody I09 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA L15-SG3249
[91]
|
Anti-BCMA antibody L15 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA M02-SG3249
[91]
|
Anti-BCMA antibody M02 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA N22-SG3249
[91]
|
Anti-BCMA antibody N22 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA P10-SG3249
[91]
|
Anti-BCMA antibody P10 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA J6M0-SG3249
[91]
|
Anti-BCMA antibody J6M0 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Anti-BCMA R347-SG3249
[91]
|
Anti-BCMA antibody R347 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
SYD998
[92]
|
Anti-PSMA mAb wt |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
SYD1091
[92]
|
Anti-PSMA mAb wt HC S41C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
SYD1035
[92]
|
Anti-PSMA mAb wt HC T120C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC152
[92]
|
Anti-PSMA mAb wt HC E152C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC153
[92]
|
Anti-PSMA mAb wt HC P153C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC236
[92]
|
Anti-PSMA mAb wt HC G236C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC247
[92]
|
Anti-PSMA mAb wt HC P247C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC339
[92]
|
Anti-PSMA mAb wt HC A339C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC375
[92]
|
Anti-PSMA mAb wt HC S375C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC376
[92]
|
Anti-PSMA mAb wt HC D376C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC41-120
[92]
|
Anti-PSMA mAb wt HC S41C/T120C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-HC41-375
[92]
|
Anti-PSMA mAb wt HC S41C/S375C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC40
[92]
|
Anti-PSMA mAb wt LC V205C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC154
[92]
|
Anti-PSMA mAb wt LC P40C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC165
[92]
|
Anti-PSMA mAb wt LC L154C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC205
[92]
|
Anti-PSMA mAb wt LC E165C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC41
[92]
|
Anti-PSMA mAb wt LC G41C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC157
[92]
|
Anti-PSMA mAb wt LC G157C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-H8-wt
[92]
|
Anti-5T4 mAb H8 wt |
Trophoblast glycoprotein (TPBG) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-LC109
[92]
|
Anti-PSMA mAb wt LC T109C |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-H8-HC40
[92]
|
Anti-5T4 mAb H8 S40C |
Trophoblast glycoprotein (TPBG) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-H8-HC41
[92]
|
Anti-5T4 mAb H8 P41C |
Trophoblast glycoprotein (TPBG) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
WO2015177360A1 ADC-Natalizumab S375C
[92]
|
Natalizumab S375C |
Integrin alpha-4 (ITGA4) |
Seco-DUBA |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
|
|
Trastuzumab-Compound 43
[93]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Trastuzumab-Compound 43 linker |
|
|
Pertuzumab-Compound 43
[93]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Pertuzumab-Compound 43 linker |
|
|
Rituximab-Compound 43
[93]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Rituximab-Compound 43 linker |
|
|
Alemtuzumab-Compound 43
[93]
|
Alemtuzumab |
CAMPATH-1 antigen (CD52) |
PBD dimer |
Alemtuzumab-Compound 43 linker |
|
|
Bevacizumab-Compound 43
[93]
|
Bevacizumab |
Vascular endothelial growth factor A (VEGFA) |
PBD dimer |
Bevacizumab-Compound 43 linker |
|
|
Adalimumab-Compound 43
[93]
|
Adalimumab |
Tumor necrosis factor (TNF) |
PBD dimer |
Adalimumab-Compound 43 linker |
|
|
Cetuximab-Compound 43
[93]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Cetuximab-Compound 43 linker |
|
|
Amatuximab-Compound 43
[93]
|
Amatuximab |
Mesothelin (MSLN) |
PBD dimer |
Amatuximab-Compound 43 linker |
|
|
Blinatumomab-Compound 43
[93]
|
Blinatumomab |
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3D) |
PBD dimer |
Blinatumomab-Compound 43 linker |
|
|
Brentuximab-Compound 43
[93]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
PBD dimer |
Brentuximab-Compound 43 linker |
|
|
Sacituzumab-Compound 43
[93]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
PBD dimer |
Sacituzumab-Compound 43 linker |
|
|
Panitumumab-Compound 43
[93]
|
Panitumumab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Panitumumab-Compound 43 linker |
|
|
Nimotuzumab-Compound 43
[93]
|
Nimotuzumab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Nimotuzumab-Compound 43 linker |
|
|
Gemtuzumab-Compound 43
[93]
|
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
PBD dimer |
Gemtuzumab-Compound 43 linker |
|
|
Golimumab-Compound 43
[93]
|
Golimumab |
Tumor necrosis factor (TNF) |
PBD dimer |
Golimumab-Compound 43 linker |
|
|
Ibritumomab-Compound 43
[93]
|
Ibritumomab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Ibritumomab-Compound 43 linker |
|
|
Infliximab-Compound 43
[93]
|
Infliximab |
Tumor necrosis factor (TNF) |
PBD dimer |
Infliximab-Compound 43 linker |
|
|
Ipilimumab-Compound 43
[93]
|
Ipilimumab |
Cytotoxic T-lymphocyte protein 4 (CTLA4) |
PBD dimer |
Ipilimumab-Compound 43 linker |
|
|
Ofatumumab-Compound 43
[93]
|
Ofatumumab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Ofatumumab-Compound 43 linker |
|
|
Tositumomab-Compound 43
[93]
|
Tositumomab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Tositumomab-Compound 43 linker |
|
|
Trastuzumab-Compound 49
[93]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Trastuzumab-Compound 49 linker |
|
|
Pertuzumab-Compound 49
[93]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Pertuzumab-Compound 49 linker |
|
|
Rituximab-Compound 49
[93]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Rituximab-Compound 49 linker |
|
|
Alemtuzumab-Compound 49
[93]
|
Alemtuzumab |
CAMPATH-1 antigen (CD52) |
PBD dimer |
Alemtuzumab-Compound 49 linker |
|
|
Bevacizumab-Compound 49
[93]
|
Bevacizumab |
Vascular endothelial growth factor A (VEGFA) |
PBD dimer |
Bevacizumab-Compound 49 linker |
|
|
Adalimumab-Compound 49
[93]
|
Adalimumab |
Tumor necrosis factor (TNF) |
PBD dimer |
Adalimumab-Compound 49 linker |
|
|
Cetuximab-Compound 49
[93]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Cetuximab-Compound 49 linker |
|
|
Amatuximab-Compound 49
[93]
|
Amatuximab |
Mesothelin (MSLN) |
PBD dimer |
Amatuximab-Compound 49 linker |
|
|
Blinatumomab-Compound 49
[93]
|
Blinatumomab |
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3D) |
PBD dimer |
Blinatumomab-Compound 49 linker |
|
|
Brentuximab-Compound 49
[93]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
PBD dimer |
Brentuximab-Compound 49 linker |
|
|
Sacituzumab-Compound 49
[93]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
PBD dimer |
Sacituzumab-Compound 49 linker |
|
|
Panitumumab-Compound 49
[93]
|
Panitumumab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Panitumumab-Compound 49 linker |
|
|
Nimotuzumab-Compound 49
[93]
|
Nimotuzumab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Nimotuzumab-Compound 49 linker |
|
|
Gemtuzumab-Compound 49
[93]
|
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
PBD dimer |
Gemtuzumab-Compound 49 linker |
|
|
Golimumab-Compound 49
[93]
|
Golimumab |
Tumor necrosis factor (TNF) |
PBD dimer |
Golimumab-Compound 49 linker |
|
|
Ibritumomab-Compound 49
[93]
|
Ibritumomab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Ibritumomab-Compound 49 linker |
|
|
Infliximab-Compound 49
[93]
|
Infliximab |
Tumor necrosis factor (TNF) |
PBD dimer |
Infliximab-Compound 49 linker |
|
|
Ipilimumab-Compound 49
[93]
|
Ipilimumab |
Cytotoxic T-lymphocyte protein 4 (CTLA4) |
PBD dimer |
Ipilimumab-Compound 49 linker |
|
|
Ofatumumab-Compound 49
[93]
|
Ofatumumab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Ofatumumab-Compound 49 linker |
|
|
Tositumomab-Compound 49
[93]
|
Tositumomab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Tositumomab-Compound 49 linker |
|
|
Trastuzumab-Compound 74
[93]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Trastuzumab-Compound 74 linker |
|
|
Pertuzumab-Compound 74
[93]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Pertuzumab-Compound 74 linker |
|
|
Rituximab-Compound 74
[93]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Rituximab-Compound 74 linker |
|
|
Alemtuzumab-Compound 74
[93]
|
Alemtuzumab |
CAMPATH-1 antigen (CD52) |
PBD dimer |
Alemtuzumab-Compound 74 linker |
|
|
Bevacizumab-Compound 74
[93]
|
Bevacizumab |
Vascular endothelial growth factor A (VEGFA) |
PBD dimer |
Bevacizumab-Compound 74 linker |
|
|
Adalimumab-Compound 74
[93]
|
Adalimumab |
Tumor necrosis factor (TNF) |
PBD dimer |
Adalimumab-Compound 74 linker |
|
|
Cetuximab-Compound 74
[93]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Cetuximab-Compound 74 linker |
|
|
Amatuximab-Compound 74
[93]
|
Amatuximab |
Mesothelin (MSLN) |
PBD dimer |
Amatuximab-Compound 74 linker |
|
|
Blinatumomab-Compound 74
[93]
|
Blinatumomab |
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3D) |
PBD dimer |
Blinatumomab-Compound 74 linker |
|
|
Brentuximab-Compound 74
[93]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
PBD dimer |
Brentuximab-Compound 74 linker |
|
|
Sacituzumab-Compound 74
[93]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
PBD dimer |
Sacituzumab-Compound 74 linker |
|
|
Panitumumab-Compound 74
[93]
|
Panitumumab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Panitumumab-Compound 74 linker |
|
|
Nimotuzumab-Compound 74
[93]
|
Nimotuzumab |
Epidermal growth factor receptor (EGFR) |
PBD dimer |
Nimotuzumab-Compound 74 linker |
|
|
Gemtuzumab-Compound 74
[93]
|
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
PBD dimer |
Gemtuzumab-Compound 74 linker |
|
|
Golimumab-Compound 74
[93]
|
Golimumab |
Tumor necrosis factor (TNF) |
PBD dimer |
Golimumab-Compound 74 linker |
|
|
Ibritumomab-Compound 74
[93]
|
Ibritumomab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Ibritumomab-Compound 74 linker |
|
|
Infliximab-Compound 74
[93]
|
Infliximab |
Tumor necrosis factor (TNF) |
PBD dimer |
Infliximab-Compound 74 linker |
|
|
Ipilimumab-Compound 74
[93]
|
Ipilimumab |
Cytotoxic T-lymphocyte protein 4 (CTLA4) |
PBD dimer |
Ipilimumab-Compound 74 linker |
|
|
Ofatumumab-Compound 74
[93]
|
Ofatumumab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Ofatumumab-Compound 74 linker |
|
|
Tositumomab-Compound 74
[93]
|
Tositumomab |
B-lymphocyte antigen CD20 (MS4A1) |
PBD dimer |
Tositumomab-Compound 74 linker |
|
|
Anti-MSL1 mAb-Compound 43
[93]
|
Anti-MSL1 mAb |
Male-specific lethal 1 homolog (MSL1) |
PBD dimer |
Anti-MSL1 mAb-Compound 43 linker |
|
|
Anti-CD59 mAb-Compound 43
[93]
|
Anti-CD59 mAb |
CD59 glycoprotein (CD59) |
PBD dimer |
Anti-CD59 mAb-Compound 43 linker |
|
|
Anti-HER2 mAb-Compound 43
[93]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Anti-HER2 mAb-Compound 43 linker |
|
|
Anti-MSL1 mAb-Compound 49
[93]
|
Anti-MSL1 mAb |
Male-specific lethal 1 homolog (MSL1) |
PBD dimer |
Anti-MSL1 mAb-Compound 49 linker |
|
|
Anti-CD59 mAb-Compound 49
[93]
|
Anti-CD59 mAb |
CD59 glycoprotein (CD59) |
PBD dimer |
Anti-CD59 mAb-Compound 49 linker |
|
|
Anti-HER2 mAb-Compound 49
[93]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Anti-HER2 mAb-Compound 49 linker |
|
|
Anti-MSL1 mAb-Compound 74
[93]
|
Anti-MSL1 mAb |
Male-specific lethal 1 homolog (MSL1) |
PBD dimer |
Anti-MSL1 mAb-Compound 74 linker |
|
|
Anti-CD59 mAb-Compound 74
[93]
|
Anti-CD59 mAb |
CD59 glycoprotein (CD59) |
PBD dimer |
Anti-CD59 mAb-Compound 74 linker |
|
|
Anti-HER2 mAb-Compound 74
[93]
|
Anti-HER2 mAb |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD dimer |
Anti-HER2 mAb-Compound 74 linker |
Investigative
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Isotype-SG3249
[94]
|
Undisclosed |
Undisclosed |
SG3199 |
Undisclosed |
|
|
Isotype-SG3376
[94]
|
Undisclosed |
Undisclosed |
SG3199 |
Undisclosed |
|
|
ADC based on linker 1 (DAR 2)
[95]
|
Undisclosed |
Staphylococcus aureus bacteria |
Mitomycin C |
Undisclosed |
|
|
ADC based on linker 1 (DAR 5)
[95]
|
Undisclosed |
Staphylococcus aureus bacteria |
Mitomycin C |
Undisclosed |
|
|
ADC based on linker 2 (DAR 2)
[95]
|
Undisclosed |
Staphylococcus aureus bacteria |
Mitomycin C |
Undisclosed |
|
|
37290045 ADC based on linker 2 (DAR 5)
[95]
|
Undisclosed |
Staphylococcus aureus bacteria |
Mitomycin C |
Undisclosed |
|
|
39757732 ADC2
[96]
|
Ab-2 |
Undisclosed |
PBD dimer |
D2 Linker |
|
|
CD117-ADC
[97]
|
Undisclosed |
Mast/stem cell growth factor receptor Kit (KIT) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
39870768 20D9h3-DUBA
[98]
|
20D9h3 |
Receptor-type tyrosine-protein kinase FLT3 (FLT3) |
Seco-DUBA |
Undisclosed |
|
|
anti TRBC1-SG3249
[99]
|
Undisclosed |
T cell receptor beta-chain constant region 1 (TRBC1) |
SG3199 |
CL2A |
|
|
Chimeric anti TRBC1-SG3249
[99]
|
Undisclosed |
T cell receptor beta-chain constant region 1 (TRBC1) |
SG3199 |
CL2A |
|
|
KK2845
[100]
|
TIM-3Ab |
T-cell immunoglobulin mucin-3 (TIM-3) |
SG3199 (SC-DR002) |
Mal-PEG8-Val-Ala-PABC |
|
|
KM8047-SG3249
[100]
|
KM8047 |
Undisclosed |
SG3199 |
Undisclosed |
|
|
CD33-ADC
[100]
|
h2H12 |
Myeloid cell surface antigen CD33 (CD33) |
SG3199 |
Undisclosed |
|
|
QLS5132
[101]
|
Anti-CLDN6 antibody |
Claudin-6 (CLDN6) |
QLS6916 |
A cleavable linker |
|
|
AM E3-SG3249
[102]
|
AM E3 |
Cytokine receptor-like factor 2 (CRLF2) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
NZ761939B 15B2GL-SG3249
[103]
|
15B2GL |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
I09-SG3249
[103]
|
I09 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
L15-SG3249
[103]
|
L15 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
M02-SG3249
[103]
|
M02 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
N22-SG3249
[103]
|
N22 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
P10-SG3249
[103]
|
P10 |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
SG3199 |
CL2A |
|
|
Trastuzumab-LD1
[104]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Seco-DUBA |
Trastuzumab-LD1-LINKER |
|
|
Trastuzumab-LD3
[104]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Seco-DUBA |
Trastuzumab-LD3-LINKER |
|
|
Trastuzumab-LD4
[104]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Seco-DUBA |
Trastuzumab-LD1-LINKER |
|
|
Trastuzumab-LD5
[104]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Seco-DUBA |
Trastuzumab-LD1-LINKER |
|
|
Trastuzumab-LD6
[104]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Seco-DUBA |
Trastuzumab-LD1-LINKER |
|
|
PSMA-HC41-LD36
[104]
|
Anti-PSMA-HC41 |
Glutamate carboxypeptidase 2 (FOLH1) |
Seco-DUBA |
PSMA-HC41-LD36 LINKER |
|
|
JP2024177330A5 18G3-CPI
[105]
|
18G3 |
Interleukin-3 receptor subunit alpha (IL3RA) |
Cyclopropylpyrroloindoline (CPI) payload |
Undisclosed |
|
|
JP2024177330A5 16D6-CPI
[105]
|
16D6 |
Interleukin-3 receptor subunit alpha (IL3RA) |
Cyclopropylpyrroloindoline (CPI) payload |
Undisclosed |
|
|
JP2024177330A5 3D1-CPI
[105]
|
3D1 |
Interleukin-3 receptor subunit alpha (IL3RA) |
Cyclopropylpyrroloindoline (CPI) payload |
Undisclosed |
|
|
JP2024177330A5 20D7-CPI
[105]
|
20D7 |
Interleukin-3 receptor subunit alpha (IL3RA) |
Cyclopropylpyrroloindoline (CPI) payload |
Undisclosed |
|
|
ZA202500202A 2188-D04-Y180-LP9
[106]
|
2188-D04-Y180 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
PBD dimer |
DBCO-PEG4-VA |
|
|
IN202417103159A 2188-D04-Yl80-LP9
[107]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
PBD |
Undisclosed |
|
|
anti-TRBC1-SG3249
[108]
|
Undisclosed |
T cell receptor beta-chain constant region 1 (TRBC1) |
SG3199 |
CL2A |
|
|
Chimeric anti-TRBC1-SG3249
[108]
|
Undisclosed |
T cell receptor beta-chain constant region 1 (TRBC1) |
SG3199 |
CL2A |
|
|
DBCO-vc-seco DUBA
[109]
|
HuSS1 |
Undisclosed |
Seco-DUBA |
EP4161582A4+DBCO-vc-seco DUBA+Linker |
|
|
DBCO-DTPA
[109]
|
HuSS1 |
Undisclosed |
Seco-DUBA |
EP4161582A4+DBCO-DTPA+Linker |
|
|
HuCL47-B1
[110]
|
HuCL47 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
B4 Payload |
US20230285580A1 B12-B2 linker |
|
|
US20230285580A1 B12-B1
[110]
|
B12 |
Undisclosed |
B4 Payload |
US20230285580A1 B12-B2 linker |
|
|
HuCL47-B6
[110]
|
HuCL47 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
B4 Payload |
US20230285580A1 B12-B6 linker |
|
|
US20230285580A1 B12-B6
[110]
|
B12 |
Undisclosed |
B4 Payload |
US20230285580A1 B12-B6 linker |
|
|
WO2024181570A1 ADC7
[111]
|
Antibody 1 |
Syndecan-1 (SDC1) |
PBD |
Mc-Val-Ala |
|
|
CD45-ADC (37567393)
[112]
|
anti-mouse CD45.2 |
Receptor-type tyrosine-protein phosphatase C (PTPRC) |
SG3199 |
Mal-PEG8-Val-Ala-PABC |
|
|
ITC-6146RO
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
Duocarmycin derivative |
Self-immolative OHPAS linker |
References